EMSAM (deprenyl patch): how a promising antidepressant was underutilized [Corrigendum]


On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb”.

On page 1921 “Both Dye and Mylan’s recent attempts at reanalysis […]” should be “Both Dey and Mylan’s recent attempts at reanalysis […]”.

On page 1921 “With over 14 years left in the patent of EMSAM, […]” should be “with 4 years left in the patent of EMSAM, […]”.

The authors apologize for these errors.